BACKGROUND: The long-term outcomes and risk factors of paclitaxel-induced peripheral neuropathy (PIPN) have not yet been fully elucidated. METHODS: We identified 219 breast cancer patients who received paclitaxel as adjuvant chemotherapy between 2002 and 2009. We retrospectively analyzed the incidence, time to onset, duration, and risk factors for PIPN by chart review. RESULTS: Of the 219 patients, 212 developed PIPN (97%) during a median follow-up time of 57 months (range 5.3-95.5). Median time to PIPN onset was 21 days (range 11-101) for the entire patient population: 35 days (range 14-77) for weekly administration and 21 days (range 11-101) for tri-weekly administration. PIPN caused termination of paclitaxel treatment in 7 patients (4%). Median duration of PIPN was 727 days (range 14-2621 days). PIPN persisted in 64 and 41% of patients at 1 and 3 years after initiating paclitaxel, respectively. Age ≥60 years and severity of PIPN were significantly associated with PIPN duration. CONCLUSIONS: PIPN persists longer in older patients and in those who experience severe neuropathy. Further studies to identify the risk factors for PIPN are warranted.
BACKGROUND: The long-term outcomes and risk factors of paclitaxel-induced peripheral neuropathy (PIPN) have not yet been fully elucidated. METHODS: We identified 219 breast cancerpatients who received paclitaxel as adjuvant chemotherapy between 2002 and 2009. We retrospectively analyzed the incidence, time to onset, duration, and risk factors for PIPN by chart review. RESULTS: Of the 219 patients, 212 developed PIPN (97%) during a median follow-up time of 57 months (range 5.3-95.5). Median time to PIPN onset was 21 days (range 11-101) for the entire patient population: 35 days (range 14-77) for weekly administration and 21 days (range 11-101) for tri-weekly administration. PIPN caused termination of paclitaxel treatment in 7 patients (4%). Median duration of PIPN was 727 days (range 14-2621 days). PIPN persisted in 64 and 41% of patients at 1 and 3 years after initiating paclitaxel, respectively. Age ≥60 years and severity of PIPN were significantly associated with PIPN duration. CONCLUSIONS:PIPN persists longer in older patients and in those who experience severe neuropathy. Further studies to identify the risk factors for PIPN are warranted.
Authors: S E Jones; J Erban; B Overmoyer; G T Budd; L Hutchins; E Lower; L Laufman; S Sundaram; W J Urba; K I Pritchard; R Mennel; D Richards; S Olsen; M L Meyers; P M Ravdin Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Wallace Akerley; James E Herndon; Merrill J Egorin; Alan P Lyss; Hedy L Kindler; Dianne M Savarese; Carol A Sherman; D Marc Rosen; Donna Hollis; Mark J Ratain; Mark R Green Journal: Cancer Date: 2003-05-15 Impact factor: 6.860
Authors: I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto Journal: Br J Pharmacol Date: 2020-06-03 Impact factor: 8.739
Authors: Jennifer R Diamond; Benjamin Wu; Neeraj Agarwal; Daniel W Bowles; Elaine T Lam; Theresa L Werner; Erik Rasmussen; Erick Gamelin; Felipe Soto; Greg Friberg; Yu-Nien Sun; Sunil Sharma Journal: Invest New Drugs Date: 2015-04-21 Impact factor: 3.850
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14
Authors: Lara Sánchez-Barroso; Maria Apellaniz-Ruiz; Gerardo Gutiérrez-Gutiérrez; María Santos; Juan M Roldán-Romero; Maria Curras; Laura Remacha; Bruna Calsina; Isabel Calvo; María Sereno; María Merino; Jesús García-Donas; Beatriz Castelo; Eva Guerra; Rocio Letón; Cristina Montero-Conde; Alberto Cascón; Lucía Inglada-Pérez; Mercedes Robledo; Cristina Rodríguez-Antona Journal: Oncologist Date: 2018-11-23
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14
Authors: Zachary A Curry; Jenny L Wilkerson; Deniz Bagdas; S Lauren Kyte; Nipa Patel; Giulia Donvito; Mohammed A Mustafa; Justin L Poklis; Micah J Niphakis; Ku-Lung Hsu; Benjamin F Cravatt; David A Gewirtz; M Imad Damaj; Aron H Lichtman Journal: J Pharmacol Exp Ther Date: 2018-03-14 Impact factor: 4.030
Authors: Ting Bao; Coby Basal; Christina Seluzicki; Susan Q Li; Andrew D Seidman; Jun J Mao Journal: Breast Cancer Res Treat Date: 2016-08-10 Impact factor: 4.872